{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T11:49:40Z","timestamp":1742989780327,"version":"3.40.3"},"publisher-location":"Cham","reference-count":311,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030404635"},{"type":"electronic","value":"9783030404642"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/10_2019_111","type":"book-chapter","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T12:02:48Z","timestamp":1580990568000},"page":"115-153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hormones, Blood Products, and Therapeutic Enzymes"],"prefix":"10.1007","author":[{"given":"Ana Catarina","family":"Silva","sequence":"first","affiliation":[]},{"given":"Cl\u00e1dia Pina","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Hugo","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Nuno","family":"Moreira","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Manuel","family":"Sousa Lobo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,9,27]]},"reference":[{"key":"111_CR1","volume-title":"Biopharmaceuticals","author":"YC Chen","year":"2018","unstructured":"Chen YC, Yeh MK (2018) Introductory chapter: biopharmaceuticals. In: Yeh MK, Chen YC (eds) Biopharmaceuticals. IntechOpen, London"},{"key":"111_CR2","volume-title":"Pharmaceutical biotechnology: concepts and applications","author":"G Walsh","year":"2013","unstructured":"Walsh G (2013) Pharmaceutical biotechnology: concepts and applications. Wiley, Hoboken"},{"key":"111_CR3","unstructured":"FaDA (2019) What are \u201cbiologics\u201d questions and answers. https:\/\/www.fda.gov\/about-fda\/about-center-biologics-evaluation-and-research-cber\/what-are-biologics-questions-and-answers"},{"key":"111_CR4","unstructured":"EMA (2019) Biological medicine. https:\/\/www.ema.europa.eu\/en\/glossary\/biological-medicine"},{"issue":"3","key":"111_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/bab.1617","volume":"65","author":"M Kesik-Brodacka","year":"2018","unstructured":"Kesik-Brodacka M (2018) Progress in biopharmaceutical development. Biotechnol Appl Biochem 65(3):306\u2013322","journal-title":"Biotechnol Appl Biochem"},{"key":"111_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jconrel.2019.01.023","volume":"296","author":"P Vass","year":"2019","unstructured":"Vass P, D\u00e9muth B, Hirsch E, Nagy B, Andersen SK, Vigh T et al (2019) Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals. J Control Release 296:162\u2013178","journal-title":"J Control Release"},{"issue":"4","key":"111_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2337\/diacare.7.4.386","volume":"7","author":"MA Permutt","year":"1984","unstructured":"Permutt MA, Chirgwin J, Rotwein P, Giddings S (1984) Insulin gene structure and function: a review of studies using recombinant DNA methodology. Diabetes Care 7(4):386\u2013394","journal-title":"Diabetes Care"},{"key":"111_CR8","first-page":"291","volume-title":"Pharmaceutical biotechnology: concepts and applications","author":"G Walsh","year":"2007","unstructured":"Walsh G (2007) Therapeutic hormones. Pharmaceutical biotechnology: concepts and applications. Wiley, Hoboken, pp 291\u2013328"},{"issue":"5","key":"111_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2174\/138920105774370599","volume":"6","author":"IM Shaikh","year":"2005","unstructured":"Shaikh IM, Jadhav KR, Ganga S, Kadam VJ, Pisal SS (2005) Advanced approaches in insulin delivery. Curr Pharm Biotechnol 6(5):387\u2013395","journal-title":"Curr Pharm Biotechnol"},{"issue":"Suppl 3","key":"111_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1365-2362.32.s3.2.x","volume":"32","author":"CJ Rhodes","year":"2002","unstructured":"Rhodes CJ, White MF (2002) Molecular insights into insulin action and secretion. Eur J Clin Invest 32(Suppl 3):3\u201313","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"111_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1042\/cs0920321","volume":"92","author":"K Docherty","year":"1997","unstructured":"Docherty K (1997) Gene therapy for diabetes mellitus. Clin Sci 92(4):321\u2013330","journal-title":"Clin Sci"},{"issue":"14","key":"111_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.gt.3301746","volume":"9","author":"A Auricchio","year":"2002","unstructured":"Auricchio A, Gao GP, Yu QC, Raper S, Rivera VM, Clackson T et al (2002) Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer. Gene Ther 9(14):963\u2013971","journal-title":"Gene Ther"},{"issue":"2","key":"111_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4103\/0976-0105.103822","volume":"3","author":"K Mane","year":"2012","unstructured":"Mane K, Chaluvaraju K, Niranjan M, Zaranappa T, Manjuthej T (2012) Review of insulin and its analogues in diabetes mellitus. J Basic Clin Pharm 3(2):283\u2013293","journal-title":"J Basic Clin Pharm"},{"issue":"7","key":"111_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0167-7799(93)90018-5","volume":"11","author":"AF Bristow","year":"1993","unstructured":"Bristow AF (1993) Recombinant-DNA-derived insulin analogues as potentially useful therapeutic agents. Trends Biotechnol 11(7):301\u2013305","journal-title":"Trends Biotechnol"},{"issue":"4585","key":"111_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1126\/science.6337396","volume":"219","author":"IS Johnson","year":"1983","unstructured":"Johnson IS (1983) Human insulin from recombinant DNA technology. Science 219(4585):632\u2013637","journal-title":"Science"},{"issue":"10","key":"111_CR16","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/dme.13692","volume":"35","author":"R Herring","year":"2018","unstructured":"Herring R, Russell-Jones DDL (2018) Lessons for modern insulin development. Diabet Med 35(10):1320\u20131328","journal-title":"Diabet Med"},{"issue":"5","key":"111_CR17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1210\/edrv.22.5.0442","volume":"22","author":"Z Vajo","year":"2001","unstructured":"Vajo Z, Fawcett J, Duckworth WC (2001) Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 22(5):706\u2013717","journal-title":"Endocr Rev"},{"key":"111_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978-1-4899-1236-7_11","volume":"5","author":"J Brange","year":"1993","unstructured":"Brange J, Langkjoer L (1993) Insulin structure and stability. Pharm Biotechnol 5:315\u2013350","journal-title":"Pharm Biotechnol"},{"key":"111_CR19","volume-title":"Pharmaceutical technology: fundamentals and applications","author":"JM Beals","year":"2008","unstructured":"Beals JM, Kovach P (2008) Insulin. In: Healthcare I (ed) Pharmaceutical technology: fundamentals and applications. Wiley, Hoboken"},{"key":"111_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12934-016-0437-3","volume":"15","author":"L Sanchez-Garcia","year":"2016","unstructured":"Sanchez-Garcia L, Martin L, Mangues R, Ferrer-Miralles N, Vazquez E, Villaverde A (2016) Recombinant pharmaceuticals from microbial cells: a 2015 update. Microb Cell Factories 15:33","journal-title":"Microb Cell Factories"},{"key":"111_CR21","unstructured":"Agency EM (2018) Semglee. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/semglee-epar-product-information_en.pdf"},{"issue":"2","key":"111_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00253-004-1809-x","volume":"67","author":"G Walsh","year":"2005","unstructured":"Walsh G (2005) Therapeutic insulins and their large-scale manufacture. Appl Microbiol Biotechnol 67(2):151\u2013159","journal-title":"Appl Microbiol Biotechnol"},{"key":"111_CR23","unstructured":"Administration FaD (1982) Humulin\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/018780s168lbl.pdf"},{"key":"111_CR24","unstructured":"Administration FaD (2012) Novolin\u00aeR. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019938s066lbl.pdf"},{"key":"111_CR25","unstructured":"Administration FaD (2011) Humulin\u00aeR. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018780s132lbl.pdf"},{"key":"111_CR26","unstructured":"Agency EM (1997) Insuman\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/insuman-epar-product-information_en.pdf"},{"key":"111_CR27","unstructured":"Agency EM (2002) Actrapid\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/actrapid-epar-product-information_en.pdf"},{"key":"111_CR28","unstructured":"Administration FaD (1999) Velosulin\u00ae BR. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/1999\/21028lbl.pdf"},{"key":"111_CR29","unstructured":"Administration FaD (2006) Exubera\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/021868lbl.pdf"},{"key":"111_CR30","unstructured":"Agency EM (2006) Exubera\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/exubera-epar-product-information_en.pdf"},{"key":"111_CR31","unstructured":"Agency EM (2007) Insulin human Winthrop. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/insulin-human-winthrop-epar-product-information_en.pdf"},{"key":"111_CR32","unstructured":"Administration FaD (2014) Afrezza\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022472lbl.pdf"},{"key":"111_CR33","unstructured":"Agency EM (2015) Solumarv. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/solumarv-0"},{"key":"111_CR34","unstructured":"Administration FaD (1996) Humalog\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020563s190lbl.pdf"},{"key":"111_CR35","unstructured":"Agency EM (1996) Humalog\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humalog-epar-product-information_en.pdf"},{"key":"111_CR36","unstructured":"Agency EM (2001) Liprolog\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/liprolog-epar-product-information_en.pdf"},{"key":"111_CR37","unstructured":"Agency EM (2017) Insulin Lispro Sanofi. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/insulin-lispro-sanofi-epar-product-information_en.pdf"},{"key":"111_CR38","unstructured":"Administration FaD (2017) Admelog\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209196s000lbl.pdf"},{"key":"111_CR39","unstructured":"Agency EM (1999) NovoRapid\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/novorapid-epar-product-information_en.pdf"},{"key":"111_CR40","unstructured":"Administration FaD (2017) Fiasp\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208751s000lbl.pdf"},{"key":"111_CR41","unstructured":"Agency EM (2017) Fiasp\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fiasp-epar-product-information_en.pdf"},{"key":"111_CR42","unstructured":"Administration FaD (2001) NovoLog Mix. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21172_Novolog_prntlbl.pdf"},{"key":"111_CR43","unstructured":"Administration FaD (2004) Apidra\u2122. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/021629lbl.pdf"},{"key":"111_CR44","unstructured":"Agency EM (2004) Apidra\u2122. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/apidra"},{"key":"111_CR45","unstructured":"Agency EM (2002) Protaphane\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/protaphane-epar-product-information_en.pdf"},{"key":"111_CR46","unstructured":"Agency EM (2002) Monotard\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/monotard-epar-product-information_en.pdf"},{"key":"111_CR47","unstructured":"Agency EM (2002) Ultratard\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ultratard-epar-product-information_en.pdf"},{"key":"111_CR48","unstructured":"Administration FaD (2000) Lantus\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2000\/21081lbl.pdf"},{"key":"111_CR49","unstructured":"Agency EM (2000) Lantus\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lantus-epar-product-information_en.pdf"},{"key":"111_CR50","unstructured":"Administration FaD (2015) Toujeo\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206538s000lbl.pdf"},{"key":"111_CR51","unstructured":"Agency EM (2000) Toujeo\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/toujeo-epar-product-information_en.pdf"},{"key":"111_CR52","unstructured":"Administration FaD (2016) Soliqua\u2122. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208673s000lbl.pdf"},{"key":"111_CR53","unstructured":"Agency EM (2017) Suliqua\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/suliqua-epar-product-information_en.pdf"},{"key":"111_CR54","unstructured":"Agency EM (2014) Abasaglar. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abasaglar-previously-abasria-epar-product-information_en.pdf"},{"key":"111_CR55","unstructured":"Administration FaD (2017) Lusduna. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2017\/208722Orig1s000TAltr.pdf"},{"key":"111_CR56","unstructured":"Agency EM (2017) Lusduna. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lusduna-epar-product-information_en.pdf"},{"key":"111_CR57","unstructured":"Administration FaD (2005) Levemir\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/021536lbl.pdf"},{"key":"111_CR58","unstructured":"Agency EM (2004) Levemir\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/levemir-epar-product-information_en.pdf"},{"key":"111_CR59","unstructured":"Administration FaD (2015) Tresiba\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/203314lbl.pdf"},{"key":"111_CR60","unstructured":"Agency EM (2013) Tresiba\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tresiba-epar-product-information_en.pdf"},{"key":"111_CR61","unstructured":"Administration FaD (2016) Xultophy\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208583s000lbl.pdf"},{"key":"111_CR62","unstructured":"Agency EM (2014) Xultophy\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xultophy-epar-product-information_en.pdf"},{"key":"111_CR63","unstructured":"Agency EM (2002) Actraphane\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/actraphane-epar-product-information_en.pdf"},{"key":"111_CR64","unstructured":"Administration FaD (1988) Mixtard\u00ae Human 70\/30. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=019585"},{"key":"111_CR65","unstructured":"Agency EM (2002) Mixtard\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mixtard-epar-product-information_en.pdf"},{"key":"111_CR66","unstructured":"Agency EM (2002) Insulatard\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/insulatard-epar-product-information_en.pdf"},{"key":"111_CR67","unstructured":"Administration FaD (1999) Humalog\u00ae Mix. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/1999\/21018lbl.pdf"},{"key":"111_CR68","unstructured":"Agency EM (2001) Liprolog Mix\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/liprolog-epar-product-information_en.pdf"},{"key":"111_CR69","unstructured":"Agency EM (2000) NovoMix\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/novomix-epar-product-information_en.pdf"},{"key":"111_CR70","unstructured":"Administration FaD (2015) Ryzodeg\u00ae 70\/30. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/203313lbl.pdf"},{"key":"111_CR71","unstructured":"Agency EM (2013) Ryzodeg\u00ae 70\/30. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ryzodeg-epar-product-information_en.pdf"},{"key":"111_CR72","unstructured":"Corporation M (2019) Afrezza\u00ae (insulin human) inhalation powder approved in Brazil. https:\/\/www.globenewswire.com\/news-release\/2019\/06\/03\/1863179\/0\/en\/Afrezza-insulin-human-Inhalation-Powder-Approved-in-Brazil.html"},{"issue":"5","key":"111_CR73","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00592-018-1113-3","volume":"55","author":"A Bhatia","year":"2018","unstructured":"Bhatia A, Tawade S, Mastim M, Kitabi EN, Gopalakrishnan M, Shah M et al (2018) Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus((R))) and Lantus((R)) in healthy subjects: a double-blind, randomized clamp study. Acta Diabetol 55(5):461\u2013468","journal-title":"Acta Diabetol"},{"key":"111_CR74","unstructured":"Administration FaD (2015) Basaglar\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/205692lbl.pdf"},{"issue":"10","key":"111_CR75","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/dme.13400","volume":"34","author":"M Davies","year":"2017","unstructured":"Davies M, Dahl D, Heise T, Kiljanski J, Mathieu C (2017) Introduction of biosimilar insulins in Europe. Diabet Med 34(10):1340\u20131353","journal-title":"Diabet Med"},{"key":"111_CR76","unstructured":"Agency EM (2015) Orphan designation: treatment of short bowel syndrome. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3151532"},{"issue":"4","key":"111_CR77","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jsps.2014.06.004","volume":"24","author":"A Muheem","year":"2016","unstructured":"Muheem A, Shakeel F, Jahangir MA, Anwar M, Mallick N, Jain GK et al (2016) A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharm J 24(4):413\u2013428","journal-title":"Saudi Pharm J"},{"issue":"6","key":"111_CR78","first-page":"553","volume":"21","author":"S Shahani","year":"2015","unstructured":"Shahani S, Shahani L (2015) Use of insulin in diabetes: a century of treatment. Hong Kong Med J 21(6):553\u2013559","journal-title":"Hong Kong Med J"},{"key":"111_CR79","unstructured":"Asquetiv (2019) MonoSol Rx announces initiation of phase 2a trial for oral insulin film. https:\/\/aquestive.com\/monosol-rx-announces-initiation-of-phase-2a-trial-for-oral-insulin-film\/"},{"key":"111_CR80","unstructured":"Trials C (2017) Comparison of insulin tregopil (IN-105) with insulin aspart in type 2 diabetes mellitus patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03430856"},{"issue":"1","key":"111_CR81","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1586\/17434440.2016.1109442","volume":"13","author":"E Cengiz","year":"2016","unstructured":"Cengiz E, Bode B, Van Name M, Tamborlane WV (2016) Moving toward the ideal insulin for insulin pumps. Expert Rev Med Devices 13(1):57\u201369","journal-title":"Expert Rev Med Devices"},{"key":"111_CR82","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-3-319-98119-2_5","volume-title":"Handbook of diabetes technology","author":"P Schaepelynck","year":"2019","unstructured":"Schaepelynck P (2019) The implantable insulin pump. Handbook of diabetes technology. Springer, Berlin, pp 47\u201355"},{"issue":"9","key":"111_CR83","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1080\/17425247.2017.1267138","volume":"14","author":"L Bally","year":"2017","unstructured":"Bally L, Thabit H, Hovorka R (2017) Finding the right route for insulin delivery \u2013 an overview of implantable pump therapy. Expert Opin Drug Deliv 14(9):1103\u20131111","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"111_CR84","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S2213-8587(17)30001-3","volume":"5","author":"L Bally","year":"2017","unstructured":"Bally L, Thabit H, Kojzar H, Mader JK, Qerimi-Hyseni J, Hartnell S et al (2017) Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. Lancet Diabetes Endocrinol 5(4):261\u2013270","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"111_CR85","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/dom.13482","volume":"21","author":"E Renard","year":"2019","unstructured":"Renard E, Tubiana-Rufi N, Bonnemaison-Gilbert E, Coutant R, Dalla-Vale F, Farret A et al (2019) Closed-loop driven by control-to-range algorithm outperforms threshold-low-glucose-suspend insulin delivery on glucose control albeit not on nocturnal hypoglycaemia in prepubertal patients with type 1 diabetes in a supervised hotel setting. Diabetes Obes Metab 21(1):183\u2013187","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"111_CR86","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1463-1326.2011.01516.x","volume":"14","author":"L Heinemann","year":"2012","unstructured":"Heinemann L, Nosek L, Flacke F, Albus K, Krasner A, Pichotta P et al (2012) U-100, pH-neutral formulation of VIAject((R)): faster onset of action than insulin lispro in patients with type 1 diabetes. Diabetes Obes Metab 14(3):222\u2013227","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"111_CR87","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/193229680800200406","volume":"2","author":"M Hompesch","year":"2008","unstructured":"Hompesch M, McManus L, Pohl R, Simms P, Pfutzner A, Bulow E et al (2008) Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. J Diabetes Sci Technol 2(4):568\u2013571","journal-title":"J Diabetes Sci Technol"},{"issue":"9","key":"111_CR88","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1007\/s00125-008-1095-8","volume":"51","author":"S Steiner","year":"2008","unstructured":"Steiner S, Hompesch M, Pohl R, Simms P, Flacke F, Mohr T et al (2008) A novel insulin formulation with a more rapid onset of action. Diabetologia 51(9):1602\u20131606","journal-title":"Diabetologia"},{"issue":"11","key":"111_CR89","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/dom.12501","volume":"17","author":"PD Home","year":"2015","unstructured":"Home PD (2015) Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? Diabetes Obes Metab 17(11):1011\u20131020","journal-title":"Diabetes Obes Metab"},{"key":"111_CR90","unstructured":"Adocia (2019) Biochaperone\u00ae Lispro. https:\/\/www.adocia.com\/products\/biochaperone-ultra-fast-analog-insulin\/"},{"issue":"S1","key":"111_CR91","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1089\/dia.2019.2505","volume":"21","author":"T Danne","year":"2019","unstructured":"Danne T, Heinemann L, Bolinder J (2019) New insulins, biosimilars, and insulin therapy. Diabetes Technol Ther 21(S1):S57\u2013S78","journal-title":"Diabetes Technol Ther"},{"key":"111_CR92","unstructured":"Lilly E (2019) Regulatory review: ultra-rapid lispro. https:\/\/www.lilly.com\/discovery\/pipeline"},{"issue":"7","key":"111_CR93","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/dom.12468","volume":"17","author":"T Heise","year":"2015","unstructured":"Heise T, Hovelmann U, Brondsted L, Adrian CL, Nosek L, Haahr H (2015) Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab 17(7):682\u2013688","journal-title":"Diabetes Obes Metab"},{"key":"111_CR94","unstructured":"Nordisk N (2015) Novo Nordisk completes phase 3a trials comparing faster-acting insulin aspart with NovoRapid\u00ae in people with type 1 and type 2 diabetes. https:\/\/www.novonordisk.com\/bin\/getPDF.1906174.pdf"},{"issue":"2","key":"111_CR95","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2337\/dc12-0808","volume":"36","author":"L Morrow","year":"2013","unstructured":"Morrow L, Muchmore DB, Hompesch M, Ludington EA, Vaughn DE (2013) Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase. Diabetes Care 36(2):273\u2013275","journal-title":"Diabetes Care"},{"issue":"11","key":"111_CR96","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/dom.12315","volume":"16","author":"SK Garg","year":"2014","unstructured":"Garg SK, Buse JB, Skyler JS, Vaughn DE, Muchmore DB (2014) Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes. Diabetes Obes Metab 16(11):1065\u20131069","journal-title":"Diabetes Obes Metab"},{"key":"111_CR97","unstructured":"Lilly E (2019) Medicines in development. https:\/\/www.lilly.com\/discovery\/pipeline"},{"key":"111_CR98","unstructured":"Lilly E (2019) LY3209590, \u201cbasal insulin-fc\u201d. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=LY3209590&cntry=&state=&city=&dist="},{"issue":"3","key":"111_CR99","first-page":"e2377","volume":"5","author":"NCCCMCM Committee","year":"2017","unstructured":"Committee NCCCMCM, Ansite J, Balamurugan AN, Barbaro B, Battle J, Brandhorst D et al (2017) Purified human pancreatic islets, CIT culture media with lisofylline or exenatide. CellR4 Repair Replace Regen Reprogram 5(3):e2377","journal-title":"CellR4 Repair Replace Regen Reprogram"},{"issue":"2","key":"111_CR100","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/13543784.2018.1428306","volume":"27","author":"T Wu","year":"2018","unstructured":"Wu T, Rayner CK, Marathe CS, Jones KL, Horowitz M (2018) Glucagon receptor signalling \u2013 backwards and forwards. Expert Opin Investig Drugs 27(2):135\u2013138","journal-title":"Expert Opin Investig Drugs"},{"key":"111_CR101","unstructured":"Patent US (2018) Glucagon analogues. https:\/\/patentimages.storage.googleapis.com\/d9\/06\/b2\/6d4c89f64b2551\/US9975939.pdf"},{"issue":"3","key":"111_CR102","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jdi.12797","volume":"9","author":"Y Hayashi","year":"2018","unstructured":"Hayashi Y, Seino Y (2018) Regulation of amino acid metabolism and alpha-cell proliferation by glucagon. J Diabetes Investig 9(3):464\u2013472","journal-title":"J Diabetes Investig"},{"issue":"3","key":"111_CR103","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/jn\/131.3.709","volume":"131","author":"DG Burrin","year":"2001","unstructured":"Burrin DG, Petersen Y, Stoll B, Sangild P (2001) Glucagon-like peptide 2: a nutrient-responsive gut growth factor. J Nutr 131(3):709\u2013712","journal-title":"J Nutr"},{"key":"111_CR104","unstructured":"Administration FaD (1998) GlucaGen\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/1998\/20918lbl.pdf"},{"key":"111_CR105","unstructured":"Administration FaD (1998) Recombinant Glucagon. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/20928.pdf"},{"key":"111_CR106","unstructured":"Agency EM (2019) Orphan designation: noninsulinoma pancreatogenous hypoglycaemia syndrome. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3182091"},{"key":"111_CR107","unstructured":"Agency EM (2019) Orphan designations: congenital hyperinsulinism. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3141342"},{"key":"111_CR108","unstructured":"Agency EM (2012) Orphan designations: congenital hyperinsulinism. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu312960"},{"key":"111_CR109","unstructured":"Agency EM (2018) Glucagon analogue linked to a human immunoglobulin Fc fragment (also known as HM15136). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3182022"},{"key":"111_CR110","unstructured":"Agency EM (2015) Saxenda\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/saxenda-epar-product-information_en.pdf"},{"key":"111_CR111","unstructured":"Administration FaD (2014) Saxenda\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206321Orig1s000lbl.pdf"},{"key":"111_CR112","unstructured":"Administration FaD (2010) Victoza\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022341lbl.pdf"},{"key":"111_CR113","unstructured":"Agency EM (2009) Victoza\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/victoza-epar-product-information_en.pdf"},{"key":"111_CR114","unstructured":"Agency EM (2018) Ozempic\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf"},{"key":"111_CR115","unstructured":"Administration FaD (2017) Ozempic\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf"},{"key":"111_CR116","unstructured":"Agency EM (2014) Trulicity\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trulicity-epar-product-information_en.pdf"},{"key":"111_CR117","unstructured":"Administration FaD (2014) Trulicity\u2122. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125469Orig1s000Lbl.pdf"},{"key":"111_CR118","unstructured":"Agency EM (2012) Revestive\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/revestive-epar-product-information_en.pdf"},{"key":"111_CR119","unstructured":"Administration FaD (2012) Gattex\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203441Orig1s000lbl.pdf"},{"key":"111_CR120","unstructured":"Agency EM (2018) Orphan designation: apraglutide. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/18\/2102-public-summary-opinion-orphan-designation-apraglutide-treatment-short-bowel-syndrome_en.pdf"},{"key":"111_CR121","unstructured":"Agency EM (2019) Orphan designation: human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/18\/2126-public-summary-opinion-orphan-designation-human-glucagon-peptide-2-analogue-linked-human_en.pdf"},{"issue":"3","key":"111_CR122","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2337\/dc17-1402","volume":"41","author":"U Hovelmann","year":"2018","unstructured":"Hovelmann U, Bysted BV, Mouritzen U, Macchi F, Lamers D, Kronshage B et al (2018) Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care 41(3):531\u2013537","journal-title":"Diabetes Care"},{"key":"111_CR123","unstructured":"Agency EM (2018) Dasiglucagon. https:\/\/www.ema.europa.eu\/en\/documents\/pip-decision\/p\/0220\/2018-ema-decision-19-july-2018-agreement-paediatric-investigation-plan-granting-deferral_en-1.pdf"},{"key":"111_CR124","unstructured":"Company ELa (2015) Intranasal glucagon: phase III clinical trials. http:\/\/lilly.mediaroom.com\/index.php?s=9042&item=137474"},{"key":"111_CR125","unstructured":"Pharmaceuticals X (2018) Xeris Pharmaceuticals announces positive phase 3 clinical trial data on its investigational ready-to-use glucagon rescue pen. https:\/\/investors.xerispharma.com\/node\/6566\/pdf"},{"key":"111_CR126","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ghir.2017.12.008","volume":"38","author":"A Caicedo","year":"2018","unstructured":"Caicedo A, Rosenfeld R (2018) Challenges and future for the delivery of growth hormone therapy. Growth Hormon IGF Res 38:39\u201343","journal-title":"Growth Hormon IGF Res"},{"key":"111_CR127","first-page":"281","volume-title":"Pharmaceutical technology: fundamentals and applications","author":"MO Marian","year":"2008","unstructured":"Marian MO, Growth Hormones J (2008) In: Healthcare I (ed) Pharmaceutical technology: fundamentals and applications. Wiley, Hoboken, pp 281\u2013292"},{"issue":"Suppl 1","key":"111_CR128","first-page":"162","volume":"16","author":"RA Lal","year":"2018","unstructured":"Lal RA, Hoffman AR (2018) Long-acting growth hormone preparations in the treatment of children. Pediatr Endocrinol Rev 16(Suppl 1):162\u2013167","journal-title":"Pediatr Endocrinol Rev"},{"key":"111_CR129","unstructured":"Administration FaD (2015) Somatropin information 2015. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/somatropin-information"},{"key":"111_CR130","unstructured":"Administration FaD (1987) Humatrope\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019640s104lbl.pdf"},{"key":"111_CR131","unstructured":"Administration FaD (2000) Norditropin\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2000\/21148lbl.pdf"},{"key":"111_CR132","unstructured":"Administration FaD (2011) Tev-Tropin\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/019774s023lbl.pdf"},{"key":"111_CR133","unstructured":"Agency EM (2013) Somatropin Biopartners. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/somatropin-biopartners-epar-product-information_en.pdf"},{"key":"111_CR134","unstructured":"Administration FaD (1987) Saizen\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/019764s086lbl.pdf"},{"key":"111_CR135","unstructured":"Agency EM (2006) Valtropin\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/valtropin-epar-product-information_en.pdf"},{"key":"111_CR136","unstructured":"Administration FaD (2007) Valtropin\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021905lbl.pdf"},{"key":"111_CR137","unstructured":"Agency EM (2013) Recombinant modified human growth hormone for the treatment of growth hormone deficiency. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/12\/1087-public-summary-opinion-orphan-designation-recombinant-modified-human-growth-hormone-treatment_en.pdf"},{"key":"111_CR138","unstructured":"Administration FaD (2001) Genotropin\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2001\/20280s31lbl.pdf"},{"key":"111_CR139","unstructured":"Administration FaD (1995) Zomacton\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/180717s048s049s050s051lbl.pdf"},{"key":"111_CR140","unstructured":"Agency EM (2006) Omnitrope\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omnitrope-epar-product-information_en.pdf"},{"key":"111_CR141","unstructured":"Administration FaD (2006) Omnitrope\u2122. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/021426lbl.pdf"},{"key":"111_CR142","unstructured":"Administration FaD (2000) Nutropin AQ\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020522s061lbl.pdf"},{"key":"111_CR143","unstructured":"Agency EM (2001) NutropinAq\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nutropinaq-epar-product-information_en.pdf"},{"key":"111_CR144","unstructured":"Administration FaD (2003) Zorbtive\u2122. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/20604s026_zorbtive_lbl.pdf"},{"key":"111_CR145","unstructured":"Administration FaD (1987) Serostim\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020604s093lbl.pdf"},{"key":"111_CR146","unstructured":"Agency EM (2000) Orphan designation: somatropin for AIDS wasting. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu300001"},{"issue":"4","key":"111_CR147","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/MED.0000000000000416","volume":"25","author":"KCJ Yuen","year":"2018","unstructured":"Yuen KCJ, Miller BS, Biller BMK (2018) The current state of long-acting growth hormone preparations for growth hormone therapy. Curr Opin Endocrinol Diabetes Obes 25(4):267\u2013273","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"111_CR148","unstructured":"Pharma A (2018) TransCon hGH. https:\/\/ascendispharma.com\/wp-content\/uploads\/2018-09-26-Boulder-Ascendis-Presentation.pdf"},{"issue":"3","key":"111_CR149","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1530\/EJE-16-0748","volume":"176","author":"CJ Strasburger","year":"2017","unstructured":"Strasburger CJ, Vanuga P, Payer J, Pfeifer M, Popovic V, Bajnok L et al (2017) MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a phase 2 study in growth hormone-deficient adults. Eur J Endocrinol 176(3):283\u2013294","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"111_CR150","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1530\/EJE-18-0185","volume":"179","author":"CR Ku","year":"2018","unstructured":"Ku CR, Brue T, Schilbach K, Ignatenko S, Magony S, Chung YS et al (2018) Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults. Eur J Endocrinol 179(3):169\u2013179","journal-title":"Eur J Endocrinol"},{"key":"111_CR151","unstructured":"ClinicalTrials.gov USNLoM (2018) Trial to compare the efficacy and safety of NNC0195-0092 (Somapacitan) with placebo and Norditropin\u00ae FlexPro\u00ae (Somatropin) in adults with growth hormone deficiency. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02229851"},{"key":"111_CR152","volume-title":"Infertility and assisted reproductive technology","author":"MJ Banker","year":"2019","unstructured":"Banker MJ, Hinduja R, Sathe S, Arora S (2019) Infertility and assisted reproductive technology1st edn. Jaypee Brothers Medical Publishers, New Delhi","edition":"1"},{"key":"111_CR153","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.theriogenology.2017.08.020","volume":"112","author":"D Ben-Menahem","year":"2018","unstructured":"Ben-Menahem D (2018) Preparation, characterization and application of long-acting FSH analogs for assisted reproduction. Theriogenology 112:11\u201317","journal-title":"Theriogenology"},{"key":"111_CR154","doi-asserted-by":"publisher","DOI":"10.1093\/acrefore\/9780190264086.013.58","volume-title":"Regulation of gonadotropins","author":"DJ Bernard","year":"2019","unstructured":"Bernard DJ, Li Y, Toufaily C, Schang G (2019) Regulation of gonadotropins. Oxford University Press, Oxford"},{"key":"111_CR155","first-page":"399","volume-title":"Pharmaceutical technology: fundamentals and applications","author":"T Sam","year":"2008","unstructured":"Sam T (2008) Follicle-stimulating hormones. In: Healthcare I (ed) Pharmaceutical technology: fundamentals and applications. Wiley, Hoboken, pp 399\u2013404"},{"issue":"6","key":"111_CR156","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1210\/er.2018-00052","volume":"39","author":"RC Anderson","year":"2018","unstructured":"Anderson RC, Newton CL, Anderson RA, Millar RP (2018) Gonadotropins and their analogs: current and potential clinical applications. Endocr Rev 39(6):911\u2013937","journal-title":"Endocr Rev"},{"key":"111_CR157","unstructured":"Agency EM (1995) Gonal-f\u00ae. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gonal-f"},{"key":"111_CR158","unstructured":"Administration FaD (1995) Gonal-f\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/20378scf015_gonal_lbl.pdf"},{"key":"111_CR159","unstructured":"Agency EM (2013) Ovaleap\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ovaleap-epar-product-information_en.pdf"},{"key":"111_CR160","unstructured":"Agency EM (2014) Bemfola\u00ae. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bemfola"},{"key":"111_CR161","unstructured":"Agency EM (1996) Puregon\u00ae. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/puregon"},{"key":"111_CR162","unstructured":"Administration FaD (2004) Follistim\u00ae AQ. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/21211_Follistim_lbl.pdf"},{"key":"111_CR163","unstructured":"Agency EM (2009) Fertavid\u00ae. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fertavid"},{"key":"111_CR164","unstructured":"Agency EM (2016) Rekovelle\u00ae. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rekovelle"},{"key":"111_CR165","unstructured":"Agency EM (2010) Elonva\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elonva-epar-product-information_en.pdf"},{"key":"111_CR166","unstructured":"Agency EM (2000) Luveris\u00ae. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/luveris"},{"key":"111_CR167","unstructured":"Administration FaD (2004) Luveris\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/021322s000_LuverisTOC.cfm"},{"key":"111_CR168","unstructured":"Agency EM (2007) Pergoveris\u00ae. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pergoveris"},{"key":"111_CR169","unstructured":"Agency EM (2001) Ovitrelle\u00ae. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ovitrelle"},{"key":"111_CR170","unstructured":"Administration FaD (2000) Ovidrel\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2000\/21149lbl.pdf"},{"issue":"1","key":"111_CR171","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4103\/jhrs.JHRS_101_18","volume":"12","author":"A Majumdar","year":"2019","unstructured":"Majumdar A, Sachan R, Nandanwar YS, Mayekar RV, Soni N, Banker MR et al (2019) A multicenter, randomized, equivalence trial of a new recombinant human chorionic gonadotropin preparation versus ovitrelle((R)) for ovulation in women undergoing intrauterine insemination following ovarian stimulation. J Hum Reprod Sci 12(1):53\u201358","journal-title":"J Hum Reprod Sci"},{"issue":"6","key":"111_CR172","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s10815-018-1172-y","volume":"35","author":"D Zander-Fox","year":"2018","unstructured":"Zander-Fox D, Lane M, Hamilton H, Tremellen K (2018) Sequential clomiphene\/corifollitrophin alpha as a technique for mild controlled ovarian hyperstimulation in IVF: a proof of concept study. J Assist Reprod Genet 35(6):1047\u20131052","journal-title":"J Assist Reprod Genet"},{"issue":"4","key":"111_CR173","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.fertnstert.2018.11.047","volume":"111","author":"M Cozzolino","year":"2019","unstructured":"Cozzolino M, Vitagliano A, Cecchino GN, Ambrosini G, Garcia-Velasco JA (2019) Corifollitropin alfa for ovarian stimulation in in vitro fertilization: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 111(4):722\u2013733","journal-title":"Fertil Steril"},{"issue":"2","key":"111_CR174","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1152\/physrev.00031.2001","volume":"82","author":"MW Szkudlinski","year":"2002","unstructured":"Szkudlinski MW, Fremont V, Ronin C, Weintraub BD (2002) Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol Rev 82(2):473\u2013502","journal-title":"Physiol Rev"},{"issue":"4","key":"111_CR175","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ecl.2018.07.003","volume":"47","author":"D Goltzman","year":"2018","unstructured":"Goltzman D (2018) Physiology of parathyroid hormone. Endocrinol Metab Clin 47(4):743\u2013758","journal-title":"Endocrinol Metab Clin"},{"key":"111_CR176","unstructured":"Agency EM (2000) Thyrogen\u00ae. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/thyrogen"},{"key":"111_CR177","unstructured":"Administration FaD (1998) Thyrogen\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/20898_Thyrogen_prntlbl.pdf"},{"key":"111_CR178","unstructured":"Agency EM (2003) Forsteo. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/forsteo-epar-product-information_en.pdf"},{"key":"111_CR179","unstructured":"Administration FaD (2002) Forteo. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/21318_forteo_lbl.pdf"},{"key":"111_CR180","unstructured":"Agency EM (2017) Terrosa\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/terrosa-epar-product-information_en.pdf"},{"key":"111_CR181","unstructured":"Agency EM (2017) Movymia\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/movymia-epar-product-information_en.pdf"},{"key":"111_CR182","unstructured":"Agency EM (2017) Natpar\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/natpar-epar-product-information_en.pdf"},{"key":"111_CR183","unstructured":"Administration FaD (2015) Natpara\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125511s000lbl.pdf"},{"key":"111_CR184","unstructured":"Pharma A (2019) TransCon PTH. https:\/\/ascendispharma.com\/product-pipeline\/transcon-pth\/"},{"issue":"1\u20132","key":"111_CR185","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijpharm.2017.10.029","volume":"535","author":"AJ Williams","year":"2018","unstructured":"Williams AJ, Jordan F, King G, Lewis AL, Illum L, Masud T et al (2018) In vitro and preclinical assessment of an intranasal spray formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis. Int J Pharm 535(1\u20132):113\u2013119","journal-title":"Int J Pharm"},{"issue":"7\u20139","key":"111_CR186","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/09205063.2017.1399001","volume":"29","author":"M Cho","year":"2018","unstructured":"Cho M, Han S, Kim H, Kim KS, Hahn SK (2018) Hyaluronate \u2013 parathyroid hormone peptide conjugate for transdermal treatment of osteoporosis. J Biomater Sci Polym Ed 29(7\u20139):793\u2013804","journal-title":"J Biomater Sci Polym Ed"},{"key":"111_CR187","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/B978-0-12-813726-0.00041-6","volume-title":"Transfusion medicine and hemostasis","author":"ST Avecilla","year":"2019","unstructured":"Avecilla ST (2019) Coagulation factor products. In: Shaz BH, Hillyer CD, Reyes Gil M (eds) Transfusion medicine and hemostasis3rd edn. Elsevier, Amsterdam, pp 251\u2013260","edition":"3"},{"key":"111_CR188","first-page":"329","volume-title":"Pharmaceutical biotechnology: concepts and applications","author":"G Walsh","year":"2007","unstructured":"Walsh G (2007) Recombinant blood products and therapeutic enzymes. In: Wiley (ed) Pharmaceutical biotechnology: concepts and applications. Wiley, Hoboken, pp 329\u2013370"},{"issue":"4","key":"111_CR189","first-page":"614","volume":"89","author":"GMN Bhopale","year":"2005","unstructured":"Bhopale GMN, Recombinant RK (2005) DNA expression products for human therapeutic use. Curr Sci 89(4):614\u2013622","journal-title":"Curr Sci"},{"issue":"2","key":"111_CR190","first-page":"48","volume":"1","author":"FM Steinberg","year":"1998","unstructured":"Steinberg FM, Raso J (1998) Biotech pharmaceuticals and biotherapy: an overview. J Pharm Pharm Sci 1(2):48\u201359","journal-title":"J Pharm Pharm Sci"},{"key":"111_CR191","first-page":"293","volume-title":"Pharmaceutical biotechnology: fundamentals and applications: informa healthcare","author":"NB Modi","year":"2008","unstructured":"Modi NB (2008) Recombinant coagulation factors and thrombolytic agents. In: Crommelin DJASR, Meibohm B (eds) Pharmaceutical biotechnology: fundamentals and applications: informa healthcare, pp 293\u2013308"},{"issue":"13","key":"111_CR192","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s40265-016-0622-z","volume":"76","author":"JE Frampton","year":"2016","unstructured":"Frampton JE (2016) Efmoroctocog alfa: a review in haemophilia A. Drugs 76(13):1281\u20131291","journal-title":"Drugs"},{"issue":"11","key":"111_CR193","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40265-017-0778-1","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM (2017) Eftrenonacog alfa: a review in haemophilia B. Drugs 77(11):1235\u20131246","journal-title":"Drugs"},{"key":"111_CR194","unstructured":"BioMarin (2019) Current clinical trials: hemophilia A. https:\/\/www.biomarin.com\/hemophilia-a"},{"key":"111_CR195","unstructured":"Therapeutics S (2019) Hemophilia B: FIXtendz study and hemophilia A: ALTA study 2019. https:\/\/www.sangamo.com\/clinical-trials"},{"key":"111_CR196","doi-asserted-by":"crossref","unstructured":"uniQure (2019) GENE THERAPY: hemophilia. http:\/\/www.uniqure.com\/gene-therapy\/hemophilia.php","DOI":"10.1182\/hematology.2019000007"},{"key":"111_CR197","unstructured":"FaDA (2018) Coagulation factors. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/coagulation-factors"},{"key":"111_CR198","unstructured":"EMA (2019) NovoSeven (eptacog alfa): an overview of NovoSeven and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/novoseven-epar-medicine-overview_en.pdf"},{"key":"111_CR199","unstructured":"FaDA (2018) Antihemophilic factor (recombinant). https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/antihemophilic-factor-recombinant"},{"key":"111_CR200","unstructured":"EMA (2018) EPAR summary for the public: Advate\u00ae (octocog alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/advate-epar-summary-public_en.pdf"},{"key":"111_CR201","unstructured":"EMA (2018) EPAR summary for the public: Kogenate Bayer (octocog alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/kogenate-bayer-epar-summary-public_en.pdf"},{"key":"111_CR202","unstructured":"EMA (2018) EPAR summary for the public: Helixate NexGen (octocog alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/helixate-nexgen-epar-summary-public_en.pdf"},{"key":"111_CR203","unstructured":"EMA (2018) EPAR summary for the public: Kovaltry (octocog alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/kovaltry-epar-summary-public_en.pdf"},{"key":"111_CR204","unstructured":"EMA (2016) EPAR summary for the public: Iblias (octocog alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/iblias-epar-summary-public_en.pdf"},{"key":"111_CR205","unstructured":"EMA (2018) NovoEight (turoctocog alfa): an overview of NovoEight and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/novoeight-epar-medicine-overview_en.pdf"},{"key":"111_CR206","unstructured":"EMA (2017) EPAR summary for the public: Afstyla (lonoctocog alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/afstyla-epar-summary-public_en.pdf"},{"key":"111_CR207","unstructured":"EMA (2015) EPAR summary for the public: Obizur (susoctocog alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/obizur-epar-summary-public_en.pdf"},{"key":"111_CR208","unstructured":"EMA (2018) EPAR summary for the public: Adynovi (rurioctocog alfa pegol). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/adynovi-epar-summary-public_en.pdf"},{"key":"111_CR209","unstructured":"EMA (2018) Jivi (damoctocog alfa pegol): an overview of Jivi and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/jivi-epar-medicine-overview_en.pdf"},{"key":"111_CR210","unstructured":"EMA (2018) Elocta (efmoroctocog alfa): an overview of Elocta and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/elocta-epar-medicine-overview_en.pdf"},{"key":"111_CR211","unstructured":"EMA (2016) EPAR summary for the public: ReFacto AF (moroctocog alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/refacto-af-epar-summary-public_en.pdf"},{"key":"111_CR212","unstructured":"EMA (2018) EPAR summary for the public: Nuwiq (simoctocog alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/nuwiq-epar-summary-public_en.pdf"},{"key":"111_CR213","unstructured":"EMA (2019) Vihuma (simoctocog alfa): an overview of Vihuma and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/vihuma-epar-medicine-overview_en.pdf"},{"key":"111_CR214","unstructured":"EMA (2018) Veyvondi (vonicog alfa): an overview of Veyvondi and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/veyvondi-epar-medicine-overview_en.pdf"},{"key":"111_CR215","unstructured":"EMA (2016) EPAR summary for the public: Alprolix (eftrenonacog alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/alprolix-epar-summary-public_en.pdf"},{"key":"111_CR216","unstructured":"EMA (2015) EPAR summary for the public: BeneFIX (nonacog alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/benefix-epar-summary-public_en.pdf"},{"key":"111_CR217","unstructured":"EMA (2015) EPAR summary for the public: Rixubis (nonacog gamma). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/rixubis-epar-summary-public_en.pdf"},{"key":"111_CR218","unstructured":"EMA (2017) EPAR summary for the public: Refixia (nonacog beta pegol). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/refixia-epar-summary-public_en.pdf"},{"key":"111_CR219","unstructured":"FaDA (2017) Prescribing information for IDELVION\u00ae. https:\/\/www.fda.gov\/media\/96526\/download"},{"key":"111_CR220","unstructured":"EMA (2016) EPAR summary for the public: Idelvion (albutrepenonacog alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/idelvion-epar-summary-public_en.pdf"},{"issue":"5","key":"111_CR221","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/0018578718788840","volume":"53","author":"DE Baker","year":"2018","unstructured":"Baker DE (2018) Coagulation factor Xa (Recombinant), inactivated-zhzo (Andexanet Alfa). Hosp Pharm 53(5):286\u2013291","journal-title":"Hosp Pharm"},{"key":"111_CR222","unstructured":"FaDA (2018) ANDEXXA (coagulation factor Xa (recombinant), inactivated-zhzo). https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/andexxa-coagulation-factor-xa-recombinant-inactivated-zhzo"},{"key":"111_CR223","unstructured":"FaDA (2018) TRETTEN\u00ae. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/tretten"},{"key":"111_CR224","unstructured":"EMA (2012) EPAR summary for the public: NovoThirteen (catridecacog). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/novothirteen-epar-summary-public_en.pdf"},{"key":"111_CR225","unstructured":"EMA (2012) Refludan (lepirudin). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/refludan"},{"key":"111_CR226","unstructured":"FaDA (2004) Prescribing information for REFLUDAN\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/020807s011lbl.pdf"},{"key":"111_CR227","unstructured":"EMA (2007) Revasc (desirudin). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/revasc"},{"key":"111_CR228","unstructured":"FaDA (2014) Prescribing information for IPRIVASK\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021271s006lbl.pdf"},{"key":"111_CR229","unstructured":"FaDA (2018) ATryn. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/atryn"},{"key":"111_CR230","unstructured":"EMA (2016) EPAR summary for the public: ATryn (antithrombin alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/atryn-epar-summary-public_en.pdf"},{"key":"111_CR231","unstructured":"EMA (2009) EPAR summary for the public: Xigris (drotrecogin alfa (activated)). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/xigris-epar-summary-public_en.pdf"},{"key":"111_CR232","unstructured":"EMA (2002) Actilyse. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/actilyse"},{"key":"111_CR233","unstructured":"FaDA (2018) Cathflo\u00ae Activase\u00ae (Alteplase). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103172s5260lbl.pdf"},{"key":"111_CR234","unstructured":"EMA (2000) Ecokinase (reteplase). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ecokinase#product-information-section"},{"key":"111_CR235","unstructured":"EMA (2016) EPAR summary for the public: rapilysin (reteplase). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/rapilysin-epar-summary-public_en.pdf"},{"key":"111_CR236","unstructured":"FaDA (2010) Reteplase product approval information \u2013 licensing action. https:\/\/web.archive.org\/web\/20130523120940\/https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/ucm093343.htm"},{"key":"111_CR237","unstructured":"EMA (2005) Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG (tenecteplase). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tenecteplase-boehringer-ingelheim-pharma-gmbh-co-kg"},{"key":"111_CR238","unstructured":"EMA (2014) EPAR summary for the public: Metalyse (tenecteplase). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/metalyse-epar-summary-public_en.pdf"},{"key":"111_CR239","unstructured":"FaDA (2018) TNKase\u00ae (Tenecteplase). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103909s5187lbl.pdf"},{"issue":"2","key":"111_CR240","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12288-013-0240-9","volume":"30","author":"TK Dutta","year":"2014","unstructured":"Dutta TK, Verma SP (2014) Rational use of recombinant factor VIIa in clinical practice. Indian J Hematol Blood Transfus 30(2):85\u201390","journal-title":"Indian J Hematol Blood Transfus"},{"key":"111_CR241","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fphar.2017.00314","volume":"8","author":"E Moorkens","year":"2017","unstructured":"Moorkens E, Meuwissen N, Huys I, Declerck P, Vulto AG, Simoens S (2017) The market of biopharmaceutical medicines: a snapshot of a diverse industrial landscape. Front Pharmacol 8:314","journal-title":"Front Pharmacol"},{"issue":"1","key":"111_CR242","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/17474086.2019.1560259","volume":"12","author":"C Biron-Andreani","year":"2019","unstructured":"Biron-Andreani C, Schved J-F (2019) Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors. Expert Rev Hematol 12(1):21\u201328","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"111_CR243","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/ejh.12366","volume":"93","author":"M Ezban","year":"2014","unstructured":"Ezban M, Vad K, Kjalke M (2014) Turoctocog alfa (NovoEight(R))--from design to clinical proof of concept. Eur J Haematol 93(5):369\u2013376","journal-title":"Eur J Haematol"},{"issue":"5","key":"111_CR244","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/MBC.0000000000000477","volume":"27","author":"H Ahmadian","year":"2016","unstructured":"Ahmadian H, Hansen EB, Faber JH, Sejergaard L, Karlsson J, Bolt G et al (2016) Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule. Blood Coagul Fibrinolysis 27(5):568\u2013575","journal-title":"Blood Coagul Fibrinolysis"},{"key":"111_CR245","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2147\/DDDT.S57967","volume":"9","author":"H Takedani","year":"2015","unstructured":"Takedani H, Hirose J (2015) Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A. Drug Des Devel Ther 9:1767\u20131772","journal-title":"Drug Des Devel Ther"},{"key":"111_CR246","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/JBM.S103796","volume":"8","author":"K Lieuw","year":"2017","unstructured":"Lieuw K (2017) Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? J Blood Med 8:67\u201373","journal-title":"J Blood Med"},{"issue":"6","key":"111_CR247","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/hae.13497","volume":"24","author":"D Baunsgaard","year":"2018","unstructured":"Baunsgaard D, Nielsen AD, Nielsen PF, Henriksen A, Kristensen AK, Bagger HW et al (2018) A comparative analysis of heterogeneity in commercially available recombinant factor VIII products. Haemophilia 24(6):880\u2013887","journal-title":"Haemophilia"},{"issue":"4","key":"111_CR248","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF03261885","volume":"26","author":"GM Keating","year":"2012","unstructured":"Keating GM, Dhillon S (2012) Octocog alfa (Advate(R)): a guide to its use in hemophilia A. BioDrugs 26(4):269\u2013273","journal-title":"BioDrugs"},{"issue":"4","key":"111_CR249","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/jth.12161","volume":"11","author":"A Tiede","year":"2013","unstructured":"Tiede A, Brand B, Fischer R, Kavakli K, Lentz SR, Matsushita T et al (2013) Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 11(4):670\u2013678","journal-title":"J Thromb Haemost"},{"key":"111_CR250","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/JBM.S82457","volume":"7","author":"TT Wynn","year":"2016","unstructured":"Wynn TT, Gumuscu B (2016) Potential role of a new PEGylated recombinant factor VIII for hemophilia A. J Blood Med 7:121\u2013128","journal-title":"J Blood Med"},{"key":"111_CR251","doi-asserted-by":"publisher","unstructured":"Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E (2019) Evolution of replacement therapy for von Willebrand disease: from plasma fraction to recombinant von Willebrand factor. Blood Rev. https:\/\/doi.org\/10.1016\/j.blre.2019.04.001","DOI":"10.1016\/j.blre.2019.04.001"},{"issue":"1","key":"111_CR252","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jth.14313","volume":"17","author":"F Peyvandi","year":"2019","unstructured":"Peyvandi F, Mamaev A, Wang J-D, Stasyshyn O, Timofeeva M, Curry N et al (2019) Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. J Thromb Haemost 17(1):52\u201362","journal-title":"J Thromb Haemost"},{"issue":"21","key":"111_CR253","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1182\/blood.V124.21.4269.4269","volume":"124","author":"M Crowther","year":"2014","unstructured":"Crowther M, Levy GG, Lu G, Leeds J, Lin J, Pratikhya P et al (2014) A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Blood 124(21):4269","journal-title":"Blood"},{"key":"111_CR254","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/JBM.S35395","volume":"5","author":"W Korte","year":"2014","unstructured":"Korte W (2014) Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency? J Blood Med 5:107\u2013113","journal-title":"J Blood Med"},{"issue":"1","key":"111_CR255","doi-asserted-by":"publisher","first-page":"7912","DOI":"10.4081\/hr.2019.7912","volume":"11","author":"G Sottilotta","year":"2019","unstructured":"Sottilotta G, Luise F, Oriana V, Piromalli A, Santacroce R, Lelio AD (2019) Use of Catridecacog in a patient with severe factor XIII deficiency undergoing surgery. Hematol Rep 11(1):7912","journal-title":"Hematol Rep"},{"issue":"02","key":"111_CR256","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1055\/s-2007-995828","volume":"24","author":"JW Fenton","year":"1998","unstructured":"Fenton JW, Ofosu FA, Brezniak DV, Hassouna HI (1998) Thrombin and antithrombotics. Semin Thromb Hemost 24(02):87\u201391","journal-title":"Semin Thromb Hemost"},{"key":"111_CR257","unstructured":"EMA (2016) EPAR summary for the public: thorinane (enoxaparin sodium). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/thorinane-epar-summary-public_en.pdf"},{"key":"111_CR258","unstructured":"EMA (2016) Lovenox and associated names. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/lovenox-associated-names"},{"key":"111_CR259","unstructured":"EMA (2019) EPAR summary for the public: Inhixa (Enoxaparin sodium). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/inhixa-epar-summary-public_en.pdf"},{"key":"111_CR260","unstructured":"FaDA (2015) Lovenox (enoxaparin) information. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/lovenox-enoxaparin-information"},{"issue":"3","key":"111_CR261","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1586\/14779072.5.3.387","volume":"5","author":"S Lee","year":"2007","unstructured":"Lee S, Gibson CM (2007) Enoxaparin in acute coronary syndromes. Expert Rev Cardiovasc Ther 5(3):387\u2013399","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"111_CR262","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/B978-0-12-813456-6.00041-2","volume-title":"Platelets","author":"A Greinacher","year":"2019","unstructured":"Greinacher A, Warkentin TE, Chong BH (2019) Heparin-induced thrombocytopenia. In: Michelson AD (ed) Platelets4th edn. Academic Press, Cambridge, pp 741\u2013767","edition":"4"},{"issue":"4966","key":"111_CR263","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1126\/science.2374926","volume":"249","author":"TJ Rydel","year":"1990","unstructured":"Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C et al (1990) The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 249(4966):277\u2013280","journal-title":"Science"},{"issue":"2","key":"111_CR264","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/0022-2836(91)80074-5","volume":"221","author":"TJ Rydel","year":"1991","unstructured":"Rydel TJ, Tulinsky A, Bode W, Huber R (1991) Refined structure of the hirudin-thrombin complex. J Mol Biol 221(2):583\u2013601","journal-title":"J Mol Biol"},{"issue":"11","key":"111_CR265","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1111\/j.1538-7836.2005.01623.x","volume":"3","author":"N Lubenow","year":"2005","unstructured":"Lubenow N, Eichler P, Lietz T, Greinacher A (2005) Lepirudin in patients with heparin-induced thrombocytopenia \u2013 results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 3(11):2428\u20132436","journal-title":"J Thromb Haemost"},{"issue":"5","key":"111_CR266","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1182\/blood-2006-02-001057","volume":"108","author":"B Tardy","year":"2006","unstructured":"Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P et al (2006) Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 108(5):1492\u20131496","journal-title":"Blood"},{"issue":"1","key":"111_CR267","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/rth2.12049","volume":"2","author":"H El-Mowafi","year":"2018","unstructured":"El-Mowafi H, El Araby A, Kandil Y, Zaghloul A (2018) Randomized, double-blind, placebo-controlled, interventional phase IV investigation to assess the efficacy and safety of r-hirudin gel (1120I.U) in patients with hematomas. Res Pract Thromb Haemost 2(1):139\u2013146","journal-title":"Res Pract Thromb Haemost"},{"key":"111_CR268","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.thromres.2018.07.008","volume":"169","author":"J Corral","year":"2018","unstructured":"Corral J, de la Morena-Barrio ME, Vicente V (2018) The genetics of antithrombin. Thromb Res 169:23\u201329","journal-title":"Thromb Res"},{"key":"111_CR269","first-page":"995","volume-title":"The first biopharmaceutical from transgenic animals: ATryn\u00ae","author":"Y Echelard","year":"2008","unstructured":"Echelard Y, Meade HM, Ziomek CA (2008) The first biopharmaceutical from transgenic animals: ATryn\u00ae. Wiley, Hoboken, pp 995\u20131020"},{"key":"111_CR270","unstructured":"EMA (2013) EPAR summary for the public: Fabrazyme (agalsidase beta). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/fabrazyme-epar-summary-public_en.pdf"},{"key":"111_CR271","unstructured":"EMA (2015) EPAR summary for the public: Replagal (agalsidase alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/replagal-epar-summary-public_en.pdf"},{"key":"111_CR272","unstructured":"FaDA (2018) Prescribing information: Fabrazyme (agalsidase beta). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103979s5303lbl.pdf"},{"issue":"4","key":"111_CR273","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0958-1669(03)00092-2","volume":"14","author":"M Vellard","year":"2003","unstructured":"Vellard M (2003) The enzyme as drug: application of enzymes as pharmaceuticals. Curr Opin Biotechnol 14(4):444\u2013450","journal-title":"Curr Opin Biotechnol"},{"key":"111_CR274","unstructured":"FaDA (2018) Prescribing information for Activase (alteplase). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103172s5259lbl.pdf"},{"key":"111_CR275","unstructured":"EMA (2018) Oncaspar (pegaspargase): an overview of Oncaspar and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/oncaspar-epar-medicines-overview_en.pdf"},{"key":"111_CR276","unstructured":"EMA (2015) EPAR summary for the public: Spectrila (asparaginase). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/spectrila-epar-summary-public_en.pdf"},{"key":"111_CR277","unstructured":"FaDA (2013) Prescribing information: ELSPAR\u00ae (asparaginase). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/101063s5169lbl.pdf"},{"key":"111_CR278","unstructured":"EMA (2012) Public summary of opinion on orphan designation: pegylated recombinant Erwinia chrysanthemi L-asparaginase for the treatment of acute lymphoblastic leukaemia. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/11\/889-public-summary-opinion-orphan-designation-pegylated-recombinant-erwinia-chrysanthemi-l_en.pdf"},{"key":"111_CR279","unstructured":"FaDA (2011) Prescribing information: ERWINAZE (asparaginase Erwinia chrysanthemi). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125359lbl.pdf"},{"key":"111_CR280","unstructured":"EMA (2018) Withdrawal of the marketing authorisation application for Graspa (L-asparaginase). https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_en.pdf"},{"key":"111_CR281","unstructured":"EMA (2009) Public summary of positive opinion for orphan designation of L-asparaginase encapsulated in erythrocytes for the treatment of pancreatic cancer. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/09\/633-public-summary-positive-opinion-orphan-designation-l-asparaginase-encapsulated-erythrocytes_en.pdf"},{"key":"111_CR282","unstructured":"EMA (2013) Public summary of opinion on orphan designation: L-asparaginase encapsulated in erythrocytes for the treatment acute myeloid leukaemia. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/13\/1106-public-summary-positive-opinion-l-asparaginase-encapsulated-erythrocytes-treatment-acute_en.pdf"},{"key":"111_CR283","unstructured":"FaDA (2014) Prescribing information: PULMOZYME\u00ae (dornase alfa). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/103532s5175lbl.pdf"},{"key":"111_CR284","unstructured":"EMA (2014) EPAR summary for the public: Vimizim (elosulfase alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/vimizim-epar-summary-public_en.pdf"},{"key":"111_CR285","unstructured":"FaDA (2014) Prescribing information: VIMIZIM (elosulfase alfa). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125460s000lbl.pdf"},{"key":"111_CR286","unstructured":"EMA (2010) EPAR summary for the public: Naglazyme (galsulfase). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/naglazyme-epar-summary-public_en.pdf"},{"key":"111_CR287","unstructured":"FaDA (2013) Prescribing information: Naglazyme (galsulfase). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125117s111lbl.pdf"},{"key":"111_CR288","unstructured":"EMA (2016) EPAR summary for the public: Elaprase (idursulfase). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/elaprase-epar-summary-public_en.pdf"},{"key":"111_CR289","unstructured":"FaDA (2018) Prescribing information: ELAPRASE\u00ae (idursulfase). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125151s197lbl.pdf"},{"key":"111_CR290","unstructured":"EMA (2015) EPAR summary for the public: Aldurazyme (laronidase). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/aldurazyme-epar-summary-public_en.pdf"},{"key":"111_CR291","unstructured":"FaDA (2003) Laronidase product approval information \u2013 licensing action. https:\/\/web.archive.org\/web\/20170118085125\/https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/ucm080438.htm"},{"key":"111_CR292","unstructured":"EMA (2010) EPAR summary for the public: Cerezyme (imiglucerase). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/cerezyme-epar-summary-public_en.pdf"},{"key":"111_CR293","unstructured":"FaDA (2003) Proposed text of the labeling of the drug: cerezyme (imiglucerase for injection). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/20367s066lbl.pdf"},{"key":"111_CR294","unstructured":"EMA (2016) EPAR summary for the public: VPRIV (velaglucerase alfa). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/vpriv-epar-summary-public_en.pdf"},{"key":"111_CR295","unstructured":"FaDA (2010) Prescribing information for VPRIV\u2122 (velaglucerase alfa for injection). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022575lbl.pdf"},{"key":"111_CR296","unstructured":"EMA (2015) EPAR summary for the public: Fasturtec (rasburicase). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/fasturtec-epar-summary-public_en.pdf"},{"key":"111_CR297","unstructured":"FaDA (2012) Rasburicase product approval information \u2013 licensing action 7\/12\/02. https:\/\/web.archive.org\/web\/20120303004138\/https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/ucm080525.htm"},{"key":"111_CR298","unstructured":"EMA (2018) Lamzede (velmanase alfa): an overview of Lamzede and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/lamzede-epar-summary-public_en.pdf"},{"issue":"2","key":"111_CR299","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ymgme.2018.04.003","volume":"124","author":"P Harmatz","year":"2018","unstructured":"Harmatz P, Cattaneo F, Ardig\u00f2 D, Geraci S, Hennermann JB, Guffon N et al (2018) Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): novel global treatment response model and outcomes in patients with alpha-mannosidosis. Mol Genet Metab 124(2):152\u2013160","journal-title":"Mol Genet Metab"},{"issue":"04","key":"111_CR300","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1160\/TH04-11-0724","volume":"93","author":"D Collen","year":"2005","unstructured":"Collen D, Lijnen RH (2005) Thrombolytic agents. Thromb Haemost 93(04):627\u2013630","journal-title":"Thromb Haemost"},{"issue":"11","key":"111_CR301","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1592\/phco.27.11.1558","volume":"27","author":"DE Hilleman","year":"2007","unstructured":"Hilleman DE, Tsikouris JP, Seals AA, Marmur JD (2007) Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy 27(11):1558\u20131570","journal-title":"Pharmacotherapy"},{"key":"111_CR302","unstructured":"FaDA (2019) Drugs@FDA: FDA approved drug products \u2013 search results for \u201calteplase\u201d. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process"},{"key":"111_CR303","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.neuropharm.2017.11.010","volume":"134","author":"A Moussaddy","year":"2018","unstructured":"Moussaddy A, Demchuk AM, Hill MD (2018) Thrombolytic therapies for ischemic stroke: triumphs and future challenges. Neuropharmacology 134:272\u2013279","journal-title":"Neuropharmacology"},{"key":"111_CR304","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/B978-0-12-805419-2.00015-0","volume-title":"Enzymes in human and animal nutrition","author":"A Kunamneni","year":"2018","unstructured":"Kunamneni A, Ogaugwu C, Goli D (2018) Enzymes as therapeutic agents. In: Nunes CS, Kumar V (eds) Enzymes in human and animal nutrition. Academic Press, Cambridge, pp 301\u2013312"},{"key":"111_CR305","unstructured":"FaDA (2003) Prescribing information for ELSPAR \u00ae (asparaginase). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/101063s5169lbl.pdf"},{"key":"111_CR306","unstructured":"EMA (2015) EPAR summary for the public: Xiapex (collagenase clostridium histolyticum). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/xiapex-epar-summary-public_en.pdf"},{"key":"111_CR307","unstructured":"EMA (2012) Prescribing information for CREON (pancrelipase). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020725s016lbl.pdf#page=16"},{"key":"111_CR308","unstructured":"FaDA (2010) Prescribing information for PANCREAZE\u2122 (pancrelipase). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022523lbl.pdf"},{"key":"111_CR309","unstructured":"FaDA (2009) Prescribing information for ZENPEP (pancrelipase). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022210s000lbl.pdf"},{"key":"111_CR310","unstructured":"FaDA (2012) Prescribing information for PERTZYE (pancrelipase). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022175s000lbl.pdf"},{"key":"111_CR311","unstructured":"FaDA (2012) Prescribing information for VIOKACE (pancrelipase). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022542s000lbl.pdf"}],"container-title":["Advances in Biochemical Engineering\/Biotechnology","Current Applications of Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/10_2019_111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T04:24:30Z","timestamp":1614313470000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/10_2019_111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030404635","9783030404642"],"references-count":311,"URL":"https:\/\/doi.org\/10.1007\/10_2019_111","relation":{},"ISSN":["0724-6145","1616-8542"],"issn-type":[{"type":"print","value":"0724-6145"},{"type":"electronic","value":"1616-8542"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"27 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}